Clinical Trial Update: Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating prophylactic emicizumab versus no prophylaxis in Hemophilia A, with results and pharmacokinetic data posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Hemlibra (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2024-03-06